Analysis of the Androgen Receptor-regulated LncRNA Landscape Identifies a Role for ARLNC1 in Prostate Cancer Progression

Overview

Journal Nat Genet

Specialty Genetics

Date 2018 May 30

PMID 29808028

Citations 119

Authors

Yajia Zhang

Sethuramasundaram Pitchiaya

Marcin Cieslik

Yashar S Niknafs

Jean C-Y Tien

Yasuyuki Hosono

Matthew K Iyer

Sahr Yazdani

Shruthi Subramaniam

Sudhanshu K Shukla

Xia Jiang

Lisha Wang

Tzu-Ying Liu

Michael Uhl

Alexander R Gawronski

Yuanyuan Qiao

Lanbo Xiao

Saravana M Dhanasekaran

Kristin M Juckette

Lakshmi P Kunju

Xuhong Cao

Utsav Patel

Mona Batish

Girish C Shukla

Michelle T Paulsen

Mats Ljungman

Hui Jiang

Rohit Mehra

Rolf Backofen

Cenk S Sahinalp

Susan M Freier

Andrew T Watt

Shuling Guo

John T Wei

Felix Y Feng

Rohit Malik

Arul M Chinnaiyan

Affiliations

Soon will be listed here.

Abstract

The androgen receptor (AR) plays a critical role in the development of the normal prostate as well as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and tissues, we identified ARLNC1 (AR-regulated long noncoding RNA 1) as an important long noncoding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only was ARLNC1 induced by the AR protein, but ARLNC1 stabilized the AR transcript via RNA-RNA interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling and prostate cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in maintaining a positive feedback loop that potentiates AR signaling during prostate cancer progression and identify ARLNC1 as a novel therapeutic target.

Citing Articles

A novel lncRNA FLJ promotes castration resistance in prostate cancer through AR mediated autophagy.

Wu Y, Cheng S, Zhang T, Wang L, Li T, Zheng Y J Transl Med. 2025; 23(1):255.

PMID: 40033417 PMC: 11874752. DOI: 10.1186/s12967-025-06294-9.

Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance.

Li C, Cheng D, Li P Front Oncol. 2025; 15:1542811.

PMID: 40008000 PMC: 11850250. DOI: 10.3389/fonc.2025.1542811.

The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance.

Lin S, Cheng Y, Lin Y, Nguyen T, Chiu W, Tsai Y Br J Cancer. 2025; .

PMID: 39956847 DOI: 10.1038/s41416-025-02938-1.

Clinical significance and biological roles of lncRNA CTBP1-AS in polycystic ovary syndrome.

Qin L, Tian C, Huang L, Qin X, Ling S, Wei J J Ovarian Res. 2024; 17(1):248.

PMID: 39702404 PMC: 11658153. DOI: 10.1186/s13048-024-01571-5.

Gene Expression Dysregulation in Whole Blood of Patients with Infection.

Tsakiroglou M, Evans A, Doce-Carracedo A, Little M, Hornby R, Roberts P Int J Mol Sci. 2024; 25(23).

PMID: 39684365 PMC: 11641058. DOI: 10.3390/ijms252312653.

References

Cieslik M, Chugh R, Wu Y, Wu M, Brennan C, Lonigro R . The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 2015; 25(9):1372-81. PMC: 4561495. DOI: 10.1101/gr.189621.115. View

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

Wutz A, Rasmussen T, Jaenisch R . Chromosomal silencing and localization are mediated by different domains of Xist RNA. Nat Genet. 2002; 30(2):167-74. DOI: 10.1038/ng820. View

Stein M, Goodin S, DiPaola R . Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res. 2012; 18(7):1848-54. PMC: 3761800. DOI: 10.1158/1078-0432.CCR-11-1805. View

Cline M, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C . Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007; 2(10):2366-82. PMC: 3685583. DOI: 10.1038/nprot.2007.324. View

Asangani I, Dommeti V, Wang X, Malik R, Cieslik M, Yang R . Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014; 510(7504):278-82. PMC: 4075966. DOI: 10.1038/nature13229. View

Chan S, Li Y, Dehm S . Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem. 2012; 287(23):19736-49. PMC: 3366007. DOI: 10.1074/jbc.M112.352930. View

Faghihi M, Modarresi F, Khalil A, Wood D, Sahagan B, Morgan T . Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008; 14(7):723-30. PMC: 2826895. DOI: 10.1038/nm1784. View

Reid A, Attard G, Danila D, Oommen N, Olmos D, Fong P . Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010; 28(9):1489-95. PMC: 2849770. DOI: 10.1200/JCO.2009.24.6819. View

10.

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

11.

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

12.

Pomerantz M, Li F, Takeda D, Lenci R, Chonkar A, Chabot M . The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015; 47(11):1346-51. PMC: 4707683. DOI: 10.1038/ng.3419. View

13.

Attard G, Richards J, de Bono J . New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res. 2011; 17(7):1649-57. PMC: 3513706. DOI: 10.1158/1078-0432.CCR-10-0567. View

14.

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002; 167(2 Pt 2):948-51; discussion 952. View

15.

Mehra R, Shi Y, Udager A, Prensner J, Sahu A, Iyer M . A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia. 2014; 16(12):1121-7. PMC: 4309259. DOI: 10.1016/j.neo.2014.11.006. View

16.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

17.

Mele M, Ferreira P, Reverter F, DeLuca D, Monlong J, Sammeth M . Human genomics. The human transcriptome across tissues and individuals. Science. 2015; 348(6235):660-5. PMC: 4547472. DOI: 10.1126/science.aaa0355. View

18.

Rhodes D, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs B . Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9(2):166-80. PMC: 1813932. DOI: 10.1593/neo.07112. View

19.

Takayama K, Horie-Inoue K, Katayama S, Suzuki T, Tsutsumi S, Ikeda K . Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 2013; 32(12):1665-80. PMC: 3680743. DOI: 10.1038/emboj.2013.99. View

20.

Scher H, Fizazi K, Saad F, Taplin M, Sternberg C, Miller K . Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367(13):1187-97. DOI: 10.1056/NEJMoa1207506. View